NASDAQ:LPTX - Leap Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.55 -0.02 (-0.78 %) (As of 01/15/2019 04:00 PM ET)Previous Close$2.57Today's Range$2.52 - $2.9352-Week Range$1.91 - $10.25Volume22,127 shsAverage Volume61,833 shsMarket Capitalization$37.35 millionP/E Ratio-0.77Dividend YieldN/ABeta2.95 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer. The company's clinical stage programs also include TRX518, a monoclonal antibody, which is in clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. It has collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate the company's TRX518, a GITR agonist, in combination with avelumab, a human anti-PD-L1 IgG1 monoclonal antibody, and chemotherapy. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts. Receive LPTX News and Ratings via Email Sign-up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LPTX Previous Symbol CUSIPN/A Webwww.leaptx.com Phone617-714-0360Debt Debt-to-Equity RatioN/A Current Ratio4.03 Quick Ratio4.03Price-To-Earnings Trailing P/E Ratio-0.77 Forward P/E Ratio-1.08 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.90 per share Price / Book2.83Profitability EPS (Most Recent Fiscal Year)($3.31) Net Income$-29,720,000.00 Net MarginsN/A Return on Equity-239.16% Return on Assets-85.07%Miscellaneous Employees22 Outstanding Shares14,700,000Market Cap$37.35 million OptionableNot Optionable Leap Therapeutics (NASDAQ:LPTX) Frequently Asked Questions What is Leap Therapeutics' stock symbol? Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX." How were Leap Therapeutics' earnings last quarter? Leap Therapeutics Inc (NASDAQ:LPTX) announced its quarterly earnings data on Thursday, November, 15th. The company reported ($0.45) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.43) by $0.02. View Leap Therapeutics' Earnings History. When is Leap Therapeutics' next earnings date? Leap Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, February 22nd 2019. View Earnings Estimates for Leap Therapeutics. What price target have analysts set for LPTX? 2 brokers have issued 12-month price objectives for Leap Therapeutics' stock. Their forecasts range from $8.00 to $13.00. On average, they anticipate Leap Therapeutics' stock price to reach $10.50 in the next year. This suggests a possible upside of 311.8% from the stock's current price. View Analyst Price Targets for Leap Therapeutics. What is the consensus analysts' recommendation for Leap Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Leap Therapeutics. What are Wall Street analysts saying about Leap Therapeutics stock? Here are some recent quotes from research analysts about Leap Therapeutics stock: 1. According to Zacks Investment Research, "Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States. " (10/6/2018) 2. HC Wainwright analysts commented, "Olga Smolentseva, Ph.D. – (646-975-6966) / [email protected] Initial DKN-01 Results Show Promise; Anti- GITR Combines Well With Chemo; Reiterate Buy Preclinical and clinical results highlights the effects of DKN-01 on the immune system. On April 16, Leap presented new results at the 2018 American Association for Cancer Research (AACR) Annual Conference that highlight the immunomodulatory effect of DKN-01 in preclinical tumor models. According to the latest results, DKN-01 is able to significantly alter the makeup of the tumor microenvironment (Exhibit 1), attract immune cells by inducing Cxcl10 expression (Exhibit 2), and improve the efficacy of PD-1 checkpoint inhibition (Exhibit 3)." (4/12/2018) Has Leap Therapeutics been receiving favorable news coverage? Media headlines about LPTX stock have been trending somewhat positive on Tuesday, according to InfoTrie. The research group scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Leap Therapeutics earned a daily sentiment score of 0.6 on InfoTrie's scale. They also gave news stories about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company's share price in the immediate future. Who are some of Leap Therapeutics' key competitors? Some companies that are related to Leap Therapeutics include Poxel (PXXLF), MOTIF BIO PLC/S (MTFB), Proteostasis Therapeutics (PTI), CytoDyn (CYDY), Marinus Pharmaceuticals (MRNS), Spero Therapeutics (SPRO), Galmed Pharmaceuticals (GLMD), Cue Biopharma (CUE), OASMIA PHARMACE/ADR (OASM), Axovant Sciences (AXON), Unum Therapeutics (UMRX), Imprimis Pharmaceuticals (IMMY), VERONA PHARMA P/S (VRNA), Northwest Biotherapeutics (NWBO) and BELLUS Health (BLUSF). Who are Leap Therapeutics' key executives? Leap Therapeutics' management team includes the folowing people: Dr. Christopher K. Mirabelli Ph.D., CEO, Pres & Chairman (Age 64)Mr. Douglas E. Onsi J.D., CFO, Gen. Counsel, Treasurer & Sec. (Age 49)Mr. Augustine J. Lawlor, Chief Operating Officer (Age 62)Dr. Cynthia A. Sirard, VP of Clinical Devel.Mr. Mark O'Mahony, VP of Manufacturing How do I buy shares of Leap Therapeutics? Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Leap Therapeutics' stock price today? One share of LPTX stock can currently be purchased for approximately $2.55. How big of a company is Leap Therapeutics? Leap Therapeutics has a market capitalization of $37.35 million. The company earns $-29,720,000.00 in net income (profit) each year or ($3.31) on an earnings per share basis. Leap Therapeutics employs 22 workers across the globe. What is Leap Therapeutics' official website? The official website for Leap Therapeutics is http://www.leaptx.com. How can I contact Leap Therapeutics? Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at 617-714-0360. MarketBeat Community Rating for Leap Therapeutics (NASDAQ LPTX)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 151 (Vote Outperform)Underperform Votes: 124 (Vote Underperform)Total Votes: 275MarketBeat's community ratings are surveys of what our community members think about Leap Therapeutics and other stocks. Vote "Outperform" if you believe LPTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LPTX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/15/2019 by MarketBeat.com StaffFeatured Article: Should You Consider an Index Fund?